14-day Premium Trial Subscription Sign Up For FreeGet Free

Amicus Therapeutics Stock Forecast NASDAQ:FOLD

Price Target and Analyst Ratings

Most Recent Rating

On July 19, 2021 "BTIG Research" gave "$15.00" rating for FOLD. The price target was changed from $8.95 to 2.3%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-07-19 $15.00 Initiated by BTIG Research $9.41 $8.95→2.3%
2021-07-01 Neutral Reiterated by Chardan Capital $9.88
2021-07-01 Hold Initiated by Berenberg Bank $9.88 $14.00
2021-06-10 Hold Reiterated by SVB Leerink $10.71
2021-05-27 Hold Initiated by Needham & Company LLC $9.00
2021-05-26 Buy Initiated by UBS Group $9.00 $16.00
2021-05-20 Buy Initiated by UBS Group $9.15 $16.00
2021-05-20 Buy Initiated by UBS Group $9.15
2021-04-19 Neutral - Overweight Upgraded by Cantor Fitzgerald $9.90
2021-04-13 Neutral - Overweight Upgraded by Cantor Fitzgerald $9.31 $17.00
2021-04-13 Neutral - Overweight Upgraded by Cantor Fitzgerald $9.31
2021-03-29 Market Perform Target Lowered by SVB Leerink $9.20 $15.00 → $13.00
2021-03-22 Market Perform Target Lowered by SVB Leerink $10.44 $15.00 → $13.00
2021-03-08 Hold Initiated by Stifel Nicolaus $10.10 $13.00
2021-03-03 Buy Reiterated by Robert W. Baird $10.66
2021-03-01 Hold Initiated by Stifel Nicolaus $11.79
2021-02-12 Overweight - Neutral Downgraded by Cantor Fitzgerald $12.57 $30.00 → $17.00
2021-02-12 Overweight - Neutral Downgraded by JPMorgan Chase & Co. $12.57
2021-02-12 Outperform - Market Perform Reiterated by SVB Leerink $12.57 $30.00 → $15.00
2021-02-12 Target Lowered by Citigroup $12.57 $27.00 → $16.00
2021-02-12 Outperform - Market Perform Downgraded by SVB Leerink $12.57 $30.00 → $15.00
2020-12-28 Overweight Initiated by Cantor Fitzgerald $23.14 $30.00 → $30.00
2020-12-14 Positive - Outperform Target Raised by SVB Leerink $23.88 $24.00 → $30.00
2020-12-14 Outperform Target Raised by SVB Leerink $23.88 $24.00 → $30.00
2020-12-10 Buy - Neutral Downgraded by Smith Barney Citigroup $21.93 $20.00 → $27.00
2020-12-10 Buy - Neutral Downgraded by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $21.93 $20.00 → $27.00
2020-11-11 Buy - Hold Initiated by Berenberg Bank $21.85
2020-11-06 Outperform Target Raised by SVB Leerink $20.47 $19.00 → $24.00
2020-11-06 Outperform Target Raised by Robert W. Baird $20.47 $20.00 → $25.00
2020-10-19 Buy Reiterated by Cowen $16.85 $31.00
2020-10-09 Overweight Reiterated by Cantor Fitzgerald $15.12
2020-08-11 Buy Reiterated by HC Wainwright $14.59 $20.00
2020-08-11 Buy Target Raised by Citigroup $14.59 $15.00 → $20.00
2020-06-16 Buy Reiterated by HC Wainwright $13.07 $20.00
2020-06-16 Buy Initiated by BTIG Research $13.07 $19.00
2020-05-19 Outperform - Market Perform Reiterated by SVB Leerink $12.26 $19.00
2020-05-18 Overweight Target Raised by JPMorgan Chase & Co. $12.61 $18.00 → $21.00

FOLD Stock Trend

Given the current short-term trend, the stock is expected to rise 24.24% during the next 3 months and, with a 90% probability hold a price between $12.65 and $15.53 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-30 $10.22 $11.38 $12.54
2021-10-01 $10.26 $11.42 $12.58
2021-10-04 $10.30 $11.46 $12.61
2021-10-05 $10.33 $11.49 $12.65
2021-10-06 $10.37 $11.53 $12.69
2021-10-07 $10.41 $11.57 $12.73
2021-10-08 $10.45 $11.61 $12.77
2021-10-11 $10.49 $11.65 $12.81
2021-10-12 $10.53 $11.69 $12.85
2021-10-13 $10.57 $11.73 $12.89
2021-10-14 $10.61 $11.76 $12.92
2021-10-15 $10.64 $11.80 $12.96
2021-10-18 $10.68 $11.84 $13.00
2021-10-19 $10.72 $11.88 $13.04
2021-10-20 $10.76 $11.92 $13.08
2021-10-21 $10.80 $11.96 $13.12
2021-10-22 $10.84 $12.00 $13.16
2021-10-25 $10.88 $12.04 $13.19
2021-10-26 $10.92 $12.07 $13.23
2021-10-27 $10.95 $12.11 $13.27
2021-10-28 $10.99 $12.15 $13.31
2021-10-29 $11.03 $12.19 $13.35
2021-11-01 $11.07 $12.23 $13.39
2021-11-02 $11.11 $12.27 $13.43
2021-11-03 $11.15 $12.31 $13.47
2021-11-04 $11.19 $12.35 $13.50
2021-11-05 $11.23 $12.38 $13.54
2021-11-08 $11.26 $12.42 $13.58
2021-11-09 $11.30 $12.46 $13.62
2021-11-10 $11.34 $12.50 $13.66

About Amicus Therapeutics

Amicus Therapeutics Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical s... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT